Minireviews
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Jan 26, 2022; 14(1): 40-53
Published online Jan 26, 2022. doi: 10.4330/wjc.v14.i1.40
Fondaparinux: A cornerstone drug in acute coronary syndromes
Mohammed Yunus Khan, Chandrashekhar K Ponde, Viveka Kumar, Kumar Gaurav
Mohammed Yunus Khan, Kumar Gaurav, Medical Affairs, Dr. Reddy's Laboratories Ltd, Hyderabad 500018, India
Chandrashekhar K Ponde, Department of Cardiology, P.D. Hinduja Hospital & Medical Research Centre, Mumbai 400016, India
Viveka Kumar, Department of Cardiology, Max Super Speciality Hospital, New Delhi 110017, India
Author contributions: Khan MY and Gaurav K developed the concept and drafted the manuscript; all authors reviewed the manuscript and gave final approval.
Conflict-of-interest statement: Mohammad Y Khan and Kumar Gaurav employees of Dr. Reddy’s laboratories. Chandrashekhar K Pande, Viveka Kumar are members of the advisory board for Dr. Reddy’s laboratories.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mohammed Yunus Khan, MD, Medical Affairs, Dr. Reddy's Laboratories Ltd, Ameerpet, Hyderabad 500018, India. doctorkhan26@gmail.com
Received: May 27, 2021
Peer-review started: May 27, 2021
First decision: July 30, 2021
Revised: August 22, 2021
Accepted: January 13, 2022
Article in press: January 13, 2022
Published online: January 26, 2022
Core Tip

Core Tip: The simultaneous use of antithrombotic therapy and anti-platelet therapy in the acute coronary syndrome acute phase is associated with reduced ischemic events and is more effective than either class of drug used alone. The physicians must maintain a balance while prescribing these drugs to maintain an overall benefit-risk ratio. Fondaparinux is one of the simple and effective anti-coagulant for the management of acute coronary syndrome.